A man in his forties lost his father to a heart attack at fifty-eight. He eats well, runs three mornings a week and gets an annual physical. Every year his doctor tells him his cholesterol is fine. Nobody has ever measured his Lp(a), the one number most likely to explain why his father died at fifty-eight, because a standard lipid panel does not report it. He is not an unusual patient. He is the normal output of a testing system that measures what is easy to bill and skips what is inherited.
If you have a family history of early heart disease, an Lp(a) test is the single most informative measurement you have probably never had. This guide explains what the test measures, who should get it, what the number means and what a high result actually changes, including what it does not change.
- Lp(a) is an LDL-like particle whose level is set almost entirely by genetics and stays roughly stable for life.
- It is an independent risk factor for heart attack, stroke and aortic valve disease and it does not appear on a standard lipid panel.
- One measurement in adulthood is usually enough, because the level barely responds to diet, exercise or statins.
- Above roughly 125 nmol/L is considered high risk and about one in five people carries an elevated level.
- A high result cannot yet be lowered much, but it changes how aggressively every controllable risk should be treated.
What Lp(a) actually is
Lipoprotein(a), spoken as L-P-little-a, is an LDL particle with an extra protein called apolipoprotein(a) attached to it. That extra protein makes the particle stickier and more prone to entering and lodging in artery walls and it carries pro-inflammatory and pro-clotting activity of its own. The result is a particle that behaves like LDL with the risk turned up.
The level in your blood is set by the LPA gene you inherited. Unlike LDL cholesterol, which responds to diet, weight, exercise and medication, Lp(a) stays roughly constant from early adulthood onward. The European Atherosclerosis Society consensus statement recommends measuring it once in a person's lifetime precisely because it is a fixed genetic trait with real consequences. About one in five people worldwide carries an elevated level and most of them have never heard of it.
There is a second risk that surprises even engaged patients. Lp(a) is associated with aortic valve stenosis, the narrowing of the heart's outflow valve, in addition to atherosclerotic disease. A population study published in JAMA found that elevated Lp(a) levels were associated with a substantially higher risk of needing valve replacement over follow-up. A number that most practices never order is linked to two of the most common serious cardiovascular outcomes and neither shows up on the standard panel.
Lp(a) vs the numbers you already have
| Question the number answers | LDL cholesterol and ApoB | Lp(a) |
|---|---|---|
| What it measures | The quantity of atherogenic particles in circulation | An inherited particle type with added stickiness and clotting activity |
| Does lifestyle change it | Yes, meaningfully | Barely at all |
| Do statins lower it | Yes, that is their main job | No and they can raise it slightly |
| How often to test | Every quarter to every year depending on risk | Usually once in a lifetime |
| Can an elevated result be treated | Yes, extensively | Not yet approved, therapies are in late-stage trials |
| What a high result changes | The treatment plan | The intensity of every other risk you can control |
That last row is the entire clinical value of the test, so it deserves unpacking before anything else.
What a high Lp(a) actually changes
The honest and slightly uncomfortable answer is that a high Lp(a) cannot be lowered much with anything your pharmacy sells today. The American Heart Association's guidance on Lp(a) is clear that lifestyle measures and statins do not meaningfully reduce it. Several RNA-based injectable therapies in late-stage trials have cut Lp(a) by large percentages and none is approved for that indication yet, so no honest clinician can promise you a prescription for it today.
So why test for a number you cannot fix? Because the number re-prices every other decision. A person with an LDL of 110 and a low Lp(a) is a different risk than a person with the same LDL and an Lp(a) of 200 nmol/L. The second person deserves a lower LDL target, earlier attention to blood pressure and HbA1c, faster escalation when markers drift and, in some cases, imaging-based screening that a risk calculator alone would not have triggered. Finding an elevated Lp(a) turns moderate risk into high risk on paper and high risk on paper is what justifies aggressive treatment of everything that moves.
There is also the family effect. Lp(a) is inherited in a dominant pattern, which means a high result is a message to your siblings and your adult children as much as it is to you. Clinicians who order the test regularly describe it as a family screening drawn from one person. No other routine measurement hands that much information to the people you love for one blood draw.
Who should get the test
Professional guidance converges on a fairly clear list. You should have Lp(a) measured at least once if any of the following applies to you.
- A family history of early cardiovascular disease, meaning a heart attack, stroke or sudden cardiac death in a parent or sibling before roughly age 55 in a man or 65 in a woman.
- An elevated ApoB or LDL cholesterol that seems out of proportion to your lifestyle, since Lp(a) inflates both.
- A personal history of atherosclerotic disease at any age, because an unmeasured Lp(a) is a missing piece of the explanation.
- A family member known to carry an elevated level, which makes you a candidate for cascade testing.
- Aortic valve disease at an early age, which the population data links to Lp(a).
If none of those applies and you simply want the deepest baseline available, the test is still reasonable and the case for it strengthens every year as therapies approach approval. The one thing we would argue against is waiting until the therapies arrive, because the entire benefit of knowing comes from the years of aggressive prevention you buy in advance.
An Lp(a) result is not a diagnosis and not a prophecy. It is one risk input among several. A person with high Lp(a), excellent blood pressure, an HbA1c of 5.2 and an ApoB of 60 carries less risk than the number suggests. A person with normal Lp(a), smoking and a HbA1c of 6.4 carries more. The value of the test is that it completes the picture rather than deciding it.
How we run the measurement
The Biomarker Audit inside our Cardiometabolic Optimization Membership includes Lp(a) alongside ApoB, hs-CRP, HbA1c, a full lipid panel, fasting insulin markers and complete hormone and thyroid panels, every 90 days, four times a year. All labs run through the Beluga Health lab network and additional testing beyond the quarterly cadence is billed to you at pass-through cost. The membership fee is $299 a month with the first charge of $598 covering the first two months combined and medication, when it is indicated, is billed separately by your pharmacy at the pharmacy's own price with zero markup from us.
We include Lp(a) in the standing panel for a practical reason rather than a philosophical one. A test that requires a special request gets skipped and a number that gets measured once in a physical gets forgotten. Four panels a year make the whole system visible in one report and make the trajectory, not the snapshot, the thing your clinician treats.
If a result comes back elevated, the clinical response is concrete. Confirm there was no acute illness inflaming the sample. Set an LDL and ApoB target lower than the standard one. Screen blood pressure and glucose markers more closely. Look at the family tree and offer testing to relatives. Watch for valve symptoms at routine reviews. None of that is dramatic and all of it compounds over decades.
The objection we hear most
The most common reason engaged adults give for skipping the test is that they do not want to know something they cannot fix. We understand the instinct and we would push back on it gently. You already carry your Lp(a) whether anyone measures it or not. The measurement does not create the risk. What it creates is a decade of better decisions in the parts of the system you can move, plus information your family can act on. Ignorance was never the protective option. It just moves the surprise to a hospital corridor.
The second objection is cost and coverage. Standalone Lp(a) testing is billed differently across plans and some insurers decline it without a qualifying history. Inside the membership there is no separate lab decision to make, because the panel includes it every quarter as part of the flat fee. One flat fee for the doctor. Zero markup on the medicine. Two separate charges, always.
For the full panel and what each marker does, read Biomarker Audits vs standard blood tests. For the model this testing lives inside, What Is GoodLife Health? Direct Primary Care, Explained covers it from first principles and the definitive guide to Cardiometabolic Optimization is the reference we hand patients in the office.
FAQ
What is an Lp(a) test?
An Lp(a) test measures lipoprotein(a), a particle in the blood that carries cholesterol in an LDL-like package with an additional protein attached. The level is set almost entirely by genetics, it stays roughly stable throughout adult life and it is not reported on a standard lipid panel. It is an independent risk factor for atherosclerotic cardiovascular disease and for aortic valve disease.
How often should Lp(a) be tested?
Most professional guidance treats Lp(a) as a once-in-a-lifetime measurement because the level is genetically determined and does not change much with diet, exercise or most medications. Our quarterly Biomarker Audit includes it so the full system is read together, but the value itself rarely moves between draws.
What is a normal Lp(a) level?
Values are reported in nmol/L or mg/dL. Under about 75 nmol/L (roughly 30 mg/dL) is generally considered low risk, 75 to 125 nmol/L is intermediate and above 125 nmol/L (roughly 50 mg/dL) is considered high risk in most guidance. Laboratories differ in units and cutoffs, so the number should be read by a clinician who can see which scale your lab used.
Can I lower my Lp(a)?
Not by much, at least not yet. Diet and exercise barely move it and statins do not lower it and can raise it slightly. Newer injectable therapies in development have lowered Lp(a) by large percentages in trials but none is approved for that purpose yet. The clinical strategy today is to find it and then manage every controllable risk more aggressively.
Does insurance cover an Lp(a) test?
Coverage varies by plan and by indication. Many plans cover it with a family history of early heart disease or an existing cardiovascular diagnosis and some decline it as standalone screening. Inside the GoodLife Health membership the Lp(a) measurement is part of the quarterly Biomarker Audit, so there is no separate lab decision to make.
I have high cholesterol and high Lp(a). Which one matters more?
They measure different things and both matter. LDL cholesterol and ApoB describe the number of atherogenic particles, which responds well to treatment. Lp(a) describes an inherited risk multiplier that barely responds to anything available today. A high Lp(a) is a reason to treat your controllable risks harder, not a reason to give up on them.
Should my family members get tested too?
Yes and this is one of the strongest reasons to test. Lp(a) runs in families, so a high result is actionable information for siblings and adult children. Many clinicians describe an Lp(a) result as a family screening test that happens to be drawn from one person.
Related Reading
- Biomarker Audits vs standard blood tests
- The definitive guide to Cardiometabolic Optimization
- What Is GoodLife Health? Direct Primary Care, Explained
References
- Lp(a): A Genetic Marker for Cardiovascular Disease (American Heart Association). 2024. www.ahajournals.org/doi/10.1161/CIR.0000000000001247
- European Atherosclerosis Society Consensus Statement on Lipoprotein(a). 2022. pubmed.ncbi.nlm.nih.gov/36332650/
- Lipoprotein(a) and Risk of Aortic Valve Stenosis (population study). 2013. pubmed.ncbi.nlm.nih.gov/24201800/